AI Engines For more Details: Perplexity Kagi Labs You
Asthma: Salmeterol is commonly prescribed as part of combination therapy for asthma, especially in cases where symptoms are not adequately controlled with other medications such as inhaled corticosteroids alone. It helps to prevent asthma symptoms such as wheezing, shortness of breath, chest tightness, and coughing. Salmeterol is not meant for the relief of acute asthma attacks but rather for long-term maintenance treatment.
Chronic Obstructive Pulmonary Disease (COPD): Salmeterol is also used in the treatment of COPD, including chronic bronchitis and emphysema. It helps to improve airflow in the lungs, reduce exacerbations, and alleviate symptoms such as shortness of breath and coughing. Like in asthma, salmeterol is used as part of combination therapy in COPD management.
Exercise-Induced Bronchoconstriction (EIB): Salmeterol can be used to prevent exercise-induced bronchoconstriction, a condition where physical activity triggers narrowing of the airways leading to symptoms like wheezing and shortness of breath. When taken before exercise, salmeterol helps to keep the airways open, thereby reducing the risk of EIB.
Prevention of Nocturnal Asthma Symptoms: Salmeterol is sometimes prescribed to prevent nocturnal asthma symptoms. By providing long-acting bronchodilation throughout the night, it can help improve sleep quality and reduce nighttime awakenings due to asthma symptoms.
Maintenance Therapy: Salmeterol is typically used as maintenance therapy, meaning it is taken regularly over an extended period to control and prevent symptoms rather than for immediate relief. It is usually prescribed in combination with an inhaled corticosteroid (ICS) for optimal asthma or COPD management.
Reduction of Airway Inflammation: While salmeterol primarily acts as a bronchodilator, it may also exert anti-inflammatory effects over time. By reducing airway inflammation, salmeterol helps to prevent exacerbations and improve lung function in individuals with asthma and COPD.
Symptom Control: By providing sustained bronchodilation for up to 12 hours after inhalation, salmeterol helps individuals with asthma and COPD maintain better control over their symptoms, leading to improved quality of life and reduced reliance on rescue medications.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Akkermansia muciniphila | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Escherichia coli | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
| species | Parabacteroides distasonis | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
| 📓 Direct Citations | 👪👶 Indirect Citations | Taxonomy | Rank | Effect |
|---|---|---|---|---|
| 0 | 1 | Akkermansiaceae | family | Decreases |
| 0 | 1 | Escherichia | genus | Decreases |
| 0 | 1 | Dorea | genus | Decreases |
| 0 | 1 | Roseburia | genus | Decreases |
| 0 | 1 | Parabacteroides | genus | Decreases |
| 1 | 0 | Akkermansia | genus | Decreases |
| 0 | 1 | Agathobacter | genus | Decreases |
| 0 | 1 | Bacteroides | genus | Decreases |
| 0 | 1 | Bifidobacterium | genus | Decreases |
| 0 | 1 | Bilophila | genus | Decreases |
| 0 | 1 | Clostridioides | genus | Decreases |
| 0 | 1 | Collinsella | genus | Decreases |
| 0 | 1 | Fusobacterium | genus | Decreases |
| 0 | 1 | Lacrimispora | genus | Decreases |
| 0 | 1 | Mediterraneibacter | genus | Decreases |
| 0 | 1 | Odoribacter | genus | Decreases |
| 0 | 1 | Streptococcus | genus | Decreases |
| 0 | 1 | Veillonella | genus | Decreases |
| 0 | 1 | Clostridium | genus | Decreases |
| 0 | 1 | Segatella | genus | Decreases |
| 0 | 1 | Enterocloster | genus | Decreases |
| 0 | 1 | Lacticaseibacillus | genus | Decreases |
| 0 | 1 | Escherichia coli O25:H16 | no rank | Decreases |
| 0 | 1 | Clostridium perfringens A | no rank | Decreases |
| 0 | 1 | Clostridium perfringens C | no rank | Decreases |
| 0 | 1 | Clostridium perfringens CPE | no rank | Decreases |
| 0 | 1 | environmental samples | no rank | Decreases |
| 0 | 1 | Escherichia coli O145:H34 | no rank | Decreases |
| 0 | 1 | Escherichia coli O16:H48 | no rank | Decreases |
| 0 | 1 | unclassified Akkermansia | no rank | Decreases |
| 0 | 1 | Clostridium perfringens D | no rank | Decreases |
| 0 | 1 | Escherichia coli O141:H4 | no rank | Decreases |
| 0 | 1 | Clostridium perfringens B | no rank | Decreases |
| 0 | 1 | Escherichia coli O139:H1 | no rank | Decreases |
| 0 | 1 | Clostridium perfringens E | no rank | Decreases |
| 0 | 1 | Escherichia coli O80:H26 | no rank | Decreases |
| 0 | 1 | Escherichia coli O158:H23 | no rank | Decreases |
| 0 | 1 | Escherichia coli O84:H7 | no rank | Decreases |
| 0 | 1 | Escherichia coli O2:K1:H4 | no rank | Decreases |
| 0 | 1 | Escherichia coli O2:K1:H7 | no rank | Decreases |
| 0 | 1 | Escherichia coli O78:H51 | no rank | Decreases |
| 0 | 1 | Escherichia coli O18ac:H14 | no rank | Decreases |
| 0 | 1 | Escherichia coli O85:H1 | no rank | Decreases |
| 0 | 1 | Escherichia coli O7:H15 | no rank | Decreases |
| 0 | 1 | Escherichia coli O68:H12 | no rank | Decreases |
| 0 | 1 | Escherichia coli O55:H7 | no rank | Decreases |
| 0 | 1 | Escherichia coli O1:K1:H7 | no rank | Decreases |
| 0 | 1 | Escherichia coli O15:H12 | no rank | Decreases |
| 0 | 1 | Escherichia coli O170:H18 | no rank | Decreases |
| 0 | 1 | Escherichia coli O155:H21 | no rank | Decreases |
| 0 | 1 | Escherichia coli O19:H7 | no rank | Decreases |
| 0 | 1 | Escherichia coli O2:K1:H5 | no rank | Decreases |
| 0 | 1 | Escherichia coli O20:H12 | no rank | Decreases |
| 0 | 1 | Escherichia coli O111 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O121 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O155 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O177 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O26 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O3 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O5 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O86 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O91 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O103 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O78 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O43 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O119 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O157 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O145 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O1:HNT | serotype | Decreases |
| 0 | 1 | Escherichia coli O10:K5(L):H4 | serotype | Decreases |
| 0 | 1 | Escherichia coli O103:H11 | serotype | Decreases |
| 0 | 1 | Escherichia coli O103:H25 | serotype | Decreases |
| 0 | 1 | Escherichia coli O104:H21 | serotype | Decreases |
| 0 | 1 | Escherichia coli O111:H11 | serotype | Decreases |
| 0 | 1 | Escherichia coli O111:H8 | serotype | Decreases |
| 0 | 1 | Escherichia coli O112ac:H19 | serotype | Decreases |
| 0 | 1 | Escherichia coli O114:H49 | serotype | Decreases |
| 0 | 1 | Escherichia coli O118:H16 | serotype | Decreases |
| 0 | 1 | Escherichia coli O121:H7 | serotype | Decreases |
| 0 | 1 | Escherichia coli O123:H11 | serotype | Decreases |
| 0 | 1 | Escherichia coli O127:H27 | serotype | Decreases |
| 0 | 1 | Escherichia coli O127:H6 | serotype | Decreases |
| 0 | 1 | Escherichia coli O128:H2 | serotype | Decreases |
| 0 | 1 | Escherichia coli O128ac:H12 | serotype | Decreases |
| 0 | 1 | Escherichia coli O145:H25 | serotype | Decreases |
| 0 | 1 | Escherichia coli O145:NM | serotype | Decreases |
| 0 | 1 | Escherichia coli O146:H21 | serotype | Decreases |
| 0 | 1 | Escherichia coli O153:H2 | serotype | Decreases |
| 0 | 1 | Escherichia coli O156:H25 | serotype | Decreases |
| 0 | 1 | Escherichia coli O157:H43 | serotype | Decreases |
| 0 | 1 | Escherichia coli O157:NM | serotype | Decreases |
| 0 | 1 | Escherichia coli O165:H25 | serotype | Decreases |
| 0 | 1 | Escherichia coli O174:H2 | serotype | Decreases |
| 0 | 1 | Escherichia coli O174:H21 | serotype | Decreases |
| 0 | 1 | Escherichia coli O174:H8 | serotype | Decreases |
| 0 | 1 | Escherichia coli O176:H45 | serotype | Decreases |
| 0 | 1 | Escherichia coli O177:NM | serotype | Decreases |
| 0 | 1 | Escherichia coli O26:H1 | serotype | Decreases |
| 0 | 1 | Escherichia coli O28ac:NM | serotype | Decreases |
| 0 | 1 | Escherichia coli O29:H4 | serotype | Decreases |
| 0 | 1 | Escherichia coli O32:H37 | serotype | Decreases |
| 0 | 1 | Escherichia coli O6:H16:CFA/II | serotype | Decreases |
| 0 | 1 | Escherichia coli O69:H11 | serotype | Decreases |
| 0 | 1 | Escherichia coli O78:H12 | serotype | Decreases |
| 0 | 1 | Escherichia coli O79:H7 | serotype | Decreases |
| 0 | 1 | Escherichia coli O81:NM | serotype | Decreases |
| 0 | 1 | Escherichia coli O86:H34 | serotype | Decreases |
| 0 | 1 | Escherichia coli O91:H14 | serotype | Decreases |
| 0 | 1 | Escherichia coli O91:NM | serotype | Decreases |
| 0 | 1 | Escherichia coli ONT:H33 | serotype | Decreases |
| 0 | 1 | Escherichia coli O100:H21 | serotype | Decreases |
| 0 | 1 | Escherichia coli O121:H19 | serotype | Decreases |
| 0 | 1 | Escherichia coli O157:H7 | serotype | Decreases |
| 0 | 1 | Escherichia coli O16:H6 | serotype | Decreases |
| 0 | 1 | Escherichia coli O89m:H9 | serotype | Decreases |
| 0 | 1 | Escherichia coli O111:H- | serotype | Decreases |
| 0 | 1 | Escherichia coli O113:H21 | serotype | Decreases |
| 0 | 1 | Escherichia coli H20 | serotype | Decreases |
| 0 | 1 | Escherichia coli O150:H6 | serotype | Decreases |
| 0 | 1 | Escherichia coli O111:NM | serotype | Decreases |
| 0 | 1 | Escherichia coli O112ab:H8 | serotype | Decreases |
| 0 | 1 | Escherichia coli O99:H6 | serotype | Decreases |
| 0 | 1 | Escherichia coli O26:H11 | serotype | Decreases |
| 0 | 1 | Escherichia coli O145:H28 | serotype | Decreases |
| 0 | 1 | Escherichia coli O126:H45 | serotype | Decreases |
| 0 | 1 | Escherichia coli O2:H6 | serotype | Decreases |
| 0 | 1 | Escherichia coli O7:H4 | serotype | Decreases |
| 0 | 1 | Escherichia coli O1:H42 | serotype | Decreases |
| 0 | 1 | Escherichia coli O25:NM | serotype | Decreases |
| 0 | 1 | Escherichia coli O25:H1 | serotype | Decreases |
| 0 | 1 | Escherichia coli O7:K1 | serotype | Decreases |
| 0 | 1 | Escherichia coli O125ac:K+:H10 | serotype | Decreases |
| 0 | 1 | Escherichia coli O6:K2:H1 | serotype | Decreases |
| 0 | 1 | Escherichia coli O152:H23 | serotype | Decreases |
| 0 | 1 | Escherichia coli O15:H18 | serotype | Decreases |
| 0 | 1 | Escherichia coli O39:NM | serotype | Decreases |
| 0 | 1 | Escherichia coli O44:H18 | serotype | Decreases |
| 0 | 1 | Escherichia coli O2:K2:H1 | serotype | Decreases |
| 0 | 1 | Escherichia coli O8:H8 | serotype | Decreases |
| 0 | 1 | Escherichia coli O89m:H10 | serotype | Decreases |
| 0 | 1 | Escherichia coli O10:H32 | serotype | Decreases |
| 0 | 1 | Escherichia coli O6:H16 | serotype | Decreases |
| 0 | 1 | Escherichia coli O157:H- | serotype | Decreases |
| 0 | 1 | Escherichia coli O45:H2 | serotype | Decreases |
| 0 | 1 | Escherichia coli O103:H2 | serotype | Decreases |
| 0 | 1 | Escherichia coli O167:H26 | serotype | Decreases |
| 0 | 1 | Escherichia coli O104:H4 | serotype | Decreases |
| 0 | 1 | Escherichia coli O83:H1 | serotype | Decreases |
| 0 | 1 | Escherichia coli O9:H10 | serotype | Decreases |
| 0 | 1 | Escherichia coli O78:H4 | serotype | Decreases |
| 0 | 1 | Escherichia coli O139:H28 | serotype | Decreases |
| 1 | 0 | Roseburia hominis | species | Decreases |
| 1 | 0 | [Ruminococcus] torques | species | Decreases |
| 1 | 0 | Agathobacter rectalis | species | Decreases |
| 1 | 0 | Akkermansia muciniphila | species | Decreases |
| 1 | 0 | Bacteroides uniformis | species | Decreases |
| 1 | 0 | Clostridioides difficile | species | Decreases |
| 1 | 0 | Parabacteroides merdae | species | Decreases |
| 1 | 0 | Roseburia intestinalis | species | Decreases |
| 1 | 0 | Collinsella aerofaciens | species | Decreases |
| 1 | 0 | Mediterraneibacter gnavus | species | Decreases |
| 1 | 0 | Parabacteroides distasonis | species | Decreases |
| 1 | 0 | Lacticaseibacillus paracasei | species | Decreases |
| 1 | 0 | Bacteroides fragilis | species | Decreases |
| 1 | 0 | Fusobacterium nucleatum | species | Decreases |
| 1 | 0 | Escherichia coli | species | Decreases |
| 1 | 0 | Veillonella parvula | species | Decreases |
| 1 | 0 | Bilophila wadsworthia | species | Decreases |
| 1 | 0 | Bacteroides caccae | species | Decreases |
| 1 | 0 | Dorea formicigenerans | species | Decreases |
| 0 | 1 | Akkermansia massiliensis | species | Decreases |
| 0 | 1 | Candidatus Akkermansia intestinavium | species | Decreases |
| 1 | 0 | Lacrimispora saccharolytica | species | Decreases |
| 1 | 0 | Segatella copri | species | Decreases |
| 1 | 0 | Bifidobacterium longum | species | Decreases |
| 1 | 0 | Bacteroides thetaiotaomicron | species | Decreases |
| 1 | 0 | Enterocloster bolteae | species | Decreases |
| 1 | 0 | Odoribacter splanchnicus | species | Decreases |
| 1 | 0 | Streptococcus salivarius | species | Decreases |
| 1 | 0 | Bifidobacterium adolescentis | species | Decreases |
| 1 | 0 | Clostridium perfringens | species | Decreases |
| 0 | 1 | Akkermansia glycaniphila | species | Decreases |
| 0 | 1 | Bifidobacterium longum subsp. longum | subspecies | Decreases |
| 0 | 1 | Bifidobacterium longum subsp. infantis | subspecies | Decreases |
| 0 | 1 | Bifidobacterium longum subsp. suis | subspecies | Decreases |
| 0 | 1 | Lacticaseibacillus paracasei subsp. paracasei | subspecies | Decreases |
| 0 | 1 | Fusobacterium nucleatum subsp. nucleatum | subspecies | Decreases |
| 0 | 1 | Lacticaseibacillus paracasei subsp. tolerans | subspecies | Decreases |
| 0 | 1 | Bifidobacterium longum subsp. suillum | subspecies | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.5 | 0.5 | |
| Acne | 0.3 | 0.9 | -2 |
| ADHD | 3.6 | 0.3 | 11 |
| Age-Related Macular Degeneration and Glaucoma | 1.1 | 0.4 | 1.75 |
| Allergic Rhinitis (Hay Fever) | 3.2 | 1.7 | 0.88 |
| Allergies | 5.5 | 2.6 | 1.12 |
| Allergy to milk products | 1.8 | 1.6 | 0.13 |
| Alopecia (Hair Loss) | 1.3 | 1.3 | |
| Alzheimer's disease | 6 | 6.6 | -0.1 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 3.2 | 1 | 2.2 |
| Ankylosing spondylitis | 4 | 1.1 | 2.64 |
| Anorexia Nervosa | 1.2 | 2.3 | -0.92 |
| Antiphospholipid syndrome (APS) | 1.5 | 0.3 | 4 |
| Asthma | 4.2 | 2.8 | 0.5 |
| Atherosclerosis | 2 | 1.9 | 0.05 |
| Atrial fibrillation | 2.9 | 2.7 | 0.07 |
| Autism | 7.9 | 7.7 | 0.03 |
| Autoimmune Disease | 1.2 | 1 | 0.2 |
| Barrett esophagus cancer | 0.6 | 0.3 | 1 |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 2 | 2 | |
| Bipolar Disorder | 1.8 | 0.8 | 1.25 |
| Brain Trauma | 0.9 | 1.1 | -0.22 |
| Breast Cancer | 1.1 | 1.1 | |
| Cancer (General) | 0.9 | 1.5 | -0.67 |
| Carcinoma | 4 | 2.2 | 0.82 |
| Celiac Disease | 2.6 | 3 | -0.15 |
| Cerebral Palsy | 1.7 | 0.8 | 1.13 |
| Chronic Fatigue Syndrome | 3.4 | 4.1 | -0.21 |
| Chronic Kidney Disease | 4.5 | 2.7 | 0.67 |
| Chronic Lyme | 0.6 | 0.8 | -0.33 |
| Chronic Obstructive Pulmonary Disease (COPD) | 1.4 | 1.4 | 0 |
| Chronic Urticaria (Hives) | 1.8 | 1.2 | 0.5 |
| Coagulation / Micro clot triggering bacteria | 1.7 | 0.8 | 1.13 |
| Cognitive Function | 2.7 | 1.6 | 0.69 |
| Colorectal Cancer | 8 | 2.3 | 2.48 |
| Constipation | 0.9 | 1.1 | -0.22 |
| Coronary artery disease | 2.4 | 2.4 | 0 |
| COVID-19 | 6.5 | 7.2 | -0.11 |
| Crohn's Disease | 7.9 | 5 | 0.58 |
| Cushing's Syndrome (hypercortisolism) | 0.3 | -0.3 | |
| cystic fibrosis | 1 | 1.2 | -0.2 |
| d-lactic acidosis (one form of brain fog) | 0.4 | 0.4 | |
| deep vein thrombosis | 2.8 | 1.1 | 1.55 |
| Denture Wearers Oral Shifts | 1.2 | 1.2 | |
| Depression | 8.5 | 9.3 | -0.09 |
| Dermatomyositis | 0.3 | 0.3 | 0 |
| Eczema | 2.2 | 1.5 | 0.47 |
| Endometriosis | 2.9 | 1.5 | 0.93 |
| Eosinophilic Esophagitis | 0.3 | 0.6 | -1 |
| Epilepsy | 3.3 | 2.6 | 0.27 |
| erectile dysfunction | 1.9 | 0.3 | 5.33 |
| Fibromyalgia | 2.6 | 1.6 | 0.63 |
| Functional constipation / chronic idiopathic constipation | 4 | 3.3 | 0.21 |
| gallstone disease (gsd) | 3.5 | 1.5 | 1.33 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.4 | 0.3 | 3.67 |
| Generalized anxiety disorder | 2.8 | 2.2 | 0.27 |
| giant cell arteritis | 0.2 | -0.2 | |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 1.3 | 0.6 | 1.17 |
| Graves' disease | 1.6 | 2.6 | -0.63 |
| Gulf War Syndrome | 0.5 | 1.9 | -2.8 |
| Halitosis | 1.6 | 0.3 | 4.33 |
| Hashimoto's thyroiditis | 3.7 | 1.8 | 1.06 |
| Heart Failure | 3.8 | 1.8 | 1.11 |
| hemorrhagic stroke | 1.3 | 1.3 | |
| Hidradenitis Suppurativa | 1.2 | 0.3 | 3 |
| High Histamine/low DAO | 1.2 | 0.3 | 3 |
| hypercholesterolemia (High Cholesterol) | 0.9 | 0.6 | 0.5 |
| hyperglycemia | 2.1 | 2 | 0.05 |
| Hyperlipidemia (High Blood Fats) | 1.2 | 0.3 | 3 |
| hypersomnia | 0.6 | -0.6 | |
| hypertension (High Blood Pressure | 4.9 | 3.9 | 0.26 |
| Hypothyroidism | 0.4 | 0.3 | 0.33 |
| Hypoxia | 3.2 | 0.5 | 5.4 |
| IgA nephropathy (IgAN) | 1.3 | 3.2 | -1.46 |
| Inflammatory Bowel Disease | 6.7 | 7.6 | -0.13 |
| Insomnia | 1.6 | 2.7 | -0.69 |
| Intelligence | 1.5 | 0.2 | 6.5 |
| Intracranial aneurysms | 1 | 0.6 | 0.67 |
| Irritable Bowel Syndrome | 7.9 | 4.2 | 0.88 |
| ischemic stroke | 2.6 | 1.7 | 0.53 |
| Liver Cirrhosis | 7 | 5 | 0.4 |
| Long COVID | 4.9 | 5 | -0.02 |
| Low bone mineral density | 0.5 | -0.5 | |
| Lung Cancer | 1.2 | 1.2 | 0 |
| Lymphoma | 0.6 | 0.6 | |
| Mast Cell Issues / mastitis | 1.3 | 0.3 | 3.33 |
| ME/CFS with IBS | 0.7 | 0.9 | -0.29 |
| ME/CFS without IBS | 1 | 1.9 | -0.9 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 0.6 | 0.9 | -0.5 |
| Metabolic Syndrome | 7.4 | 7.1 | 0.04 |
| Mood Disorders | 8.5 | 6.9 | 0.23 |
| multiple chemical sensitivity [MCS] | 1.1 | 1.1 | |
| Multiple Sclerosis | 4.9 | 4 | 0.23 |
| Multiple system atrophy (MSA) | 1.6 | 0.3 | 4.33 |
| myasthenia gravis | 0.9 | 0.7 | 0.29 |
| neuropathic pain | 2.7 | -2.7 | |
| Neuropathy (all types) | 0.7 | 2.3 | -2.29 |
| neuropsychiatric disorders (PANDAS, PANS) | 1 | 1 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 4 | 3.3 | 0.21 |
| NonCeliac Gluten Sensitivity | 1.5 | 0.6 | 1.5 |
| Obesity | 10.4 | 7.7 | 0.35 |
| obsessive-compulsive disorder | 3.9 | 4 | -0.03 |
| Osteoarthritis | 2.5 | 1.2 | 1.08 |
| Osteoporosis | 1.9 | 1.8 | 0.06 |
| pancreatic cancer | 1 | 0.3 | 2.33 |
| Parkinson's Disease | 7.8 | 5.7 | 0.37 |
| Polycystic ovary syndrome | 5 | 2.6 | 0.92 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.3 | -0.5 |
| Premenstrual dysphoric disorder | 0.6 | 0.4 | 0.5 |
| primary biliary cholangitis | 1.2 | 1.7 | -0.42 |
| Primary sclerosing cholangitis | 2.1 | 1.6 | 0.31 |
| Psoriasis | 3.1 | 3.1 | 0 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 6.2 | 4.1 | 0.51 |
| Rosacea | 0.9 | 1 | -0.11 |
| Schizophrenia | 4.8 | 2.4 | 1 |
| scoliosis | 0.4 | 0.3 | 0.33 |
| Sjögren syndrome | 2.4 | 2.6 | -0.08 |
| Sleep Apnea | 1.2 | 0.8 | 0.5 |
| Slow gastric motility / Gastroparesis | 1 | 0.3 | 2.33 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.8 | 0.2 | 8 |
| Stress / posttraumatic stress disorder | 3.4 | 2.4 | 0.42 |
| Systemic Lupus Erythematosus | 3.9 | 1.3 | 2 |
| Tic Disorder | 0.6 | 1.3 | -1.17 |
| Tourette syndrome | 1.2 | 0.3 | 3 |
| Type 1 Diabetes | 3 | 2.3 | 0.3 |
| Type 2 Diabetes | 7.3 | 6.9 | 0.06 |
| Ulcerative colitis | 4.6 | 5.9 | -0.28 |
| Unhealthy Ageing | 4.8 | 2.5 | 0.92 |
| Vitiligo | 1.7 | 1.3 | 0.31 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]
